The British Columbia Athletic Commission on Thursday revealed that Ali Bagautinov tested positive for erythropoietin (EPO) during a random drug test prior to his UFC 174 challenge of flyweight champion Demetrious Johnson.
Due to the processing time at the laboratory, the results of the June 2 drug test weren’t known until after Bagautinov had already lost a five-round unanimous decision to Johnson on June 14 in Vancouver. The BCAC revoked Bagautinov’s license and suspended him for one year.
The Ultimate Fighting Championship on Thursday threw its full support behind the BCAC’s decision, adding that Bagautinov must pass a drug test before he can gain clearance to ever fight in the UFC again.
The UFC statement on Ali Bagautinov:
“UFC 174 competitor Ali Bagautinov has been suspended by the British Columbia Athletic Commission for testing positive for erythropoietin (EPO). He was also informed that his positive test violated the UFC Fighter Conduct Policy and Promotional Agreement with Zuffa, LLC. The UFC has a strict, consistent policy against the use of any illegal and/or performance-enhancing drugs, stimulants or masking agents by our athletes. Bagautinov will serve a one-year suspension and must pass a drug test at the conclusion of his suspension before receiving clearance to compete in the UFC again.”